Dr. Thomas Dyrberg Thomas Dyrberg obtained his M.D. degree from the University of Copenhagen in 1981 and his D.M.Sc. degree, also from the University of Copenhagen in 1986. He held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, USA. In 1990 he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development as an International Clinical Project Manager. Thomas Dyrberg joined Novo A/S in December 2000 and in addition serves on the boards of Veloxis Pharmaceuticals A/S, Ophthotech Corp, Lux Biosciences, Inc. and Allocure, Inc.

© 2012 Delenex Therapeutics AG | Wagistrasse 27 | CH-8952 Schlieren/Zürich | Switzerland